Clin2
NCT04409860Possibly a fitRecruiting

Adjuvant chemo after chemoradiation for advanced cervical cancer

Cervical Cancer

Treatments studied

Part of Cancer, Women’s health & pregnancy clinical trials.

This trial looks at whether adding chemotherapy after standard chemoradiation helps people with locally advanced cervical cancer. You may be eligible if your MRI after treatment still shows leftover tumor areas and your health and blood tests are within required limits.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
120 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Your cervical cancer is stage IIb to IVa, and the tumor type is squamous, adenosquamous, or adenocarcinoma
  • You finished standard chemoradiation (radiation to set dose ranges plus chemotherapy with a platinum drug like cisplatin or carboplatin)
  • You had an MRI within 4 weeks after chemoradiation that still shows residual lesions of the required size (not just lymph nodes, or lymph nodes above a certain minimum size)
  • Your day-to-day function is okay (ECOG less than 2) and you’re expected to live more than 6 months
  • Your blood counts and organ labs are high enough for treatment (hemoglobin, white blood cells/ANC, platelets, and acceptable liver/kidney results)
  • If you can become pregnant, your pregnancy test must be negative and you must use effective birth control during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05173272Recruiting· Phase 3
Immunotherapy plus chemo, then radiation, for advanced cervical cancer

This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.

Chengdu, Sichuan
NCT06426056Not yet recruiting· Phase 2
Nab-paclitaxel plus cisplatin with radiation for advanced cervical cancer

This trial tests a combination of chemotherapy (nab-paclitaxel plus cisplatin) given together with radiation therapy for people with locally advanced cervical cancer. The goal is to see if this treatment is safe and effective.

NCT05764044Recruiting· Phase 3
Chemo after chemoradiation for HPV-positive cervical cancer

This Phase 3 study tests whether giving additional (adjuvant) chemotherapy after standard chemoradiation can help people whose blood test still shows cancer-related HPV DNA. It may help by lowering the risk of the cervical cancer coming back in people who have a positive blood biomarker after treatment.

Manaus, Amazonas
NCT04733820Recruiting· Phase 3
Extra chemo after surgery for advanced cervical cancer

This Phase 3 trial tests whether adding chemotherapy after surgery helps people with locally advanced cervical cancer, especially when prior treatment didn’t fully match standard guidelines. It looks at whether this “adjuvant” chemotherapy improves outcomes after neoadjuvant chemotherapy and an extensive hysterectomy.

Wuhan, Hubei
NCT05367206Recruiting· Phase 3
Tested chemotherapy before chemoradiation for advanced cervical cancer

This trial compares two treatment plans for stage IIIC cervical cancer: giving chemotherapy first, then chemoradiation, versus going straight to chemoradiation. It may help doctors see which approach works better for shrinking the cancer before and during radiation.

Guangzhou, Guangdone
NCT06288373Recruiting· Phase 2/Phase 3
Comparing chemoimmunotherapy vs chemoradiation for advanced cervical cancer before surgery

This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.

Hefei, Anhui

Hear when a new Cervical Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.